nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

INTRODUCTION: Despite improvements in the treatment of advanced non-small cell lung cancer (NSCLC), certain patient populations remain underrepresented in clinical trials. Many patients have benefited from platinum doublets, including nab-paclitaxel–based regimens, but there are patients with comorb...

Descripción completa

Detalles Bibliográficos
Autores principales: Langer, Corey J., Gajra, Ajeet, Gridelli, Cesare, Konduri, Kartik, Morgensztern, Daniel, Spigel, David, Talbot, Denis, Thomas, Michael, Weiss, Jared, Pilot, Richard, Bhore, Rafia, Wolfsteiner, Marianne, Ong, Teng Jin, Socinski, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871002/
https://www.ncbi.nlm.nih.gov/pubmed/33575203
http://dx.doi.org/10.3389/fonc.2020.485587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871002/
https://www.ncbi.nlm.nih.gov/pubmed/33575203
http://dx.doi.org/10.3389/fonc.2020.485587

Ejemplares similares